Q3 2018 Earnings Estimate for Lannett Company, Inc. (LCI) Issued By Oppenheimer

Lannett Company, Inc. (NYSE:LCI) – Stock analysts at Oppenheimer cut their Q3 2018 earnings per share (EPS) estimates for shares of Lannett in a report released on Wednesday. Oppenheimer analyst D. Archila now expects that the company will post earnings per share of $0.76 for the quarter, down from their prior forecast of $0.95. Oppenheimer currently has a “Hold” rating on the stock. Oppenheimer also issued estimates for Lannett’s Q4 2018 earnings at $0.69 EPS, FY2018 earnings at $3.12 EPS, FY2019 earnings at $3.08 EPS, FY2020 earnings at $2.84 EPS and FY2021 earnings at $2.91 EPS.

LCI has been the subject of a number of other research reports. BMO Capital Markets raised their price objective on Lannett from $20.00 to $22.00 and gave the stock a “market perform” rating in a research report on Monday, November 13th. Zacks Investment Research cut Lannett from a “buy” rating to a “hold” rating in a research report on Tuesday, November 14th. ValuEngine raised Lannett from a “hold” rating to a “buy” rating in a research report on Thursday, November 9th. Goldman Sachs Group started coverage on Lannett in a research report on Wednesday, January 24th. They issued a “neutral” rating and a $21.00 price objective for the company. Finally, Roth Capital set a $25.00 price objective on Lannett and gave the stock a “buy” rating in a research report on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $20.83.

Shares of Lannett (NYSE LCI) opened at $17.95 on Monday. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.32 and a quick ratio of 1.90. The firm has a market capitalization of $676.71, a price-to-earnings ratio of 14.13, a PEG ratio of 1.13 and a beta of 2.51. Lannett has a 52-week low of $14.90 and a 52-week high of $30.35.

Lannett (NYSE:LCI) last announced its earnings results on Wednesday, February 7th. The company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.86 by $0.20. The business had revenue of $184.31 million for the quarter, compared to analysts’ expectations of $190.92 million. Lannett had a return on equity of 18.85% and a net margin of 7.44%. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.92 EPS.

Institutional investors and hedge funds have recently modified their holdings of the business. Voya Investment Management LLC lifted its position in Lannett by 82.5% during the 2nd quarter. Voya Investment Management LLC now owns 46,757 shares of the company’s stock worth $954,000 after acquiring an additional 21,131 shares during the period. Schwab Charles Investment Management Inc. raised its stake in shares of Lannett by 6.2% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 153,632 shares of the company’s stock valued at $3,135,000 after buying an additional 9,005 shares during the last quarter. Frontier Capital Management Co. LLC purchased a new position in shares of Lannett during the 4th quarter valued at about $21,367,000. SG Americas Securities LLC raised its stake in shares of Lannett by 53.2% during the 3rd quarter. SG Americas Securities LLC now owns 70,667 shares of the company’s stock valued at $1,304,000 after buying an additional 24,544 shares during the last quarter. Finally, Nationwide Fund Advisors raised its stake in shares of Lannett by 192.7% during the 3rd quarter. Nationwide Fund Advisors now owns 77,123 shares of the company’s stock valued at $1,423,000 after buying an additional 50,774 shares during the last quarter. 99.69% of the stock is owned by institutional investors.

In other Lannett news, CEO Arthur P. Bedrosian sold 50,000 shares of Lannett stock in a transaction dated Friday, November 24th. The stock was sold at an average price of $26.75, for a total transaction of $1,337,500.00. Following the completion of the sale, the chief executive officer now owns 636,616 shares of the company’s stock, valued at approximately $17,029,478. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Arthur P. Bedrosian sold 42,000 shares of Lannett stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $25.50, for a total value of $1,071,000.00. Following the sale, the chief executive officer now directly owns 636,616 shares of the company’s stock, valued at approximately $16,233,708. The disclosure for this sale can be found here. Insiders sold a total of 122,578 shares of company stock valued at $3,243,757 in the last three months. Insiders own 14.72% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/12/q3-2018-earnings-estimate-for-lannett-company-inc-lci-issued-by-oppenheimer.html.

About Lannett

Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

Earnings History and Estimates for Lannett (NYSE:LCI)

Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply